

(12) International Application Status Report

Received at International Bureau: 05 December 2017 (05.12.2017)

Information valid as of: 01 April 2019 (01.04.2019)

Report generated on: 26 April 2019 (26.04.2019)

(10) Publication number: WO2018/100558	(43) Publication date: 07 June 2018 (07.06.2018)	(26) Publication language: English (EN)
(21) Application Number: PCT/IB2017/057588	(22) Filing Date: 01 December 2017 (01.12.2017)	(25) Filing language: English (EN)
(31) Priority number(s): 2016-234553 (JP) 2017-107216 (JP) 62/589,300 (US)	(31) Priority date(s): 01 December 2016 (01.12.2016) 30 May 2017 (30.05.2017) 21 November 2017 (21.11.2017)	(31) Priority status: Priority document received (in compliance with PCT Rule 17.1) Priority document received (in compliance with PCT Rule 17.1) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

C07H 21/00 (2006.01); **C07H 21/02** (2006.01); **A61K 31/7084** (2006.01); **A61P 35/00** (2006.01)

(71) Applicant(s):

TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi Osaka, 541-0045 (JP) *(for all designated states)*

(72) Inventor(s):

YOSHIKAWA, Masato; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SAITOH, Morihisa; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
KATO, Taisuke; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
YOSHITOMI, Yayoi; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SEKI, Tomohiro; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
NAKAGAWA, Yasuo; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
TOMINARI, Yusuke; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SETO, Masaki; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SASAKI, Yusuke; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
OKANIWA, Masanori; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
ODA, Tsuneo; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SHIBUYA, Akito; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
HIDAKA, Kosuke; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SHIOKAWA, Zenyu; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
MURATA, Shumpei; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)

OKABE, Atsutoshi; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)

NAKADA, Yoshihisa; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)

MOCHIZUKI, Michiyo; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)

FREEZE, Brian Scott; 67 Gates St, Unit 1 Boston, Massachusetts 02127 (US)

TAWARAISHI, Taisuke; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)

WADA, Yasufumi; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)

GREENSPAN, Paul D.; 8 Overlook Drive Acton, Massachusetts 01720 (US)

(54) Title (EN): CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS

(54) Title (FR): DINUCLÉOTIDE CYCLIQUE

(57) Abstract:

(EN): The present disclosure provides a compound having a STING (stimulator of interferon genes) agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases, such as cancer. The present disclosure relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.

(FR): La présente invention concerne un composé ayant une activité agoniste de STING, dont on s'attend à ce qu'il soit utile en tant qu'agent pour la prophylaxie ou le traitement de maladies associées à STING. La présente invention concerne un composé représenté par la formule (I), dans laquelle chaque symbole est tel que défini dans la spécification, ou un sel de celui-ci.

International search report:

Received at International Bureau: 06 June 2018 (06.06.2018) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM